Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Drugs for Infections and Infectious Diseases in Phase II Clinical Development in CHINA

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Ascletis Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Ascletis Announces Positive Phase IIa HBV Results on Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)

              Contact the Supplier

              Lead Product(s): Envafolimab

              Therapeutic Area: Infections and Infectious Diseases Product Name: ASC22

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 05, 2021

              Details:

              The phase IIa data indicated that there is a trend of dose dependent HBsAg reduction after single dose administration of 0.3, 1.0 or 2.5 mg/kg ASC22. Eight out of nine patients treated with ASC22 exhibited some decline in HBsAg at the end of 12-week follow-up.

              LianBio